Shots:

• The companies enter in a global Ab manufacturing collaboration to expedite the global supply of Lilly's COVID-19 therapies
•  With the agreement- the two companies will have the ability to ramp up the production and serve more patients globally- once Lilly's Ab therapies prove successful in clinical testing and receive regulatory approval
• Lilly is currently evaluating multiple neutralizing Abs for the prevention and/or treatment of COVID-19 as either monothx. or as combination therapy. Amgen will leverage its technical expertise in antibody development and capabilities in the scale-up and manufacturing of complex biologics

­ Ref: PRNewswire | Image: Eli Lilly